ACRIVON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.25 USD | -1.23% |
|
-6.09% | +47.36% |
| 05-14 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-30 | North American Morning Briefing : More Earnings -2- | DJ |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 240.6 | 109.2 | 223.9 | - | - |
| Enterprise Value (EV) 1 | 112.8 | 109.2 | 223.9 | 223.9 | 223.9 |
| P/E ratio | -1.52 x | -1.8 x | -3 x | -2.91 x | -2.86 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 222 x | 10.8 x |
| EV / Revenue | - | - | - | 222 x | 10.8 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | -7.45 x | - | -3.47 x | -2.65 x | -2.05 x |
| FCF Yield | -13.4% | - | -28.8% | -37.8% | -48.7% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,885 | 22,194 | 30,877 | - | - |
| Reference price 2 | 11.52 | 4.920 | 7.250 | 7.250 | 7.250 |
| Announcement Date | 23-03-28 | 24-03-28 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 1.009 | 20.71 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -32.66 | -67.1 | -78.71 | -101.1 | -108 |
| Operating Margin | - | - | - | - | -10,014.9% | -521.71% |
| Earnings before Tax (EBT) 1 | - | -31.17 | -60.39 | -74.76 | -96.23 | -105.7 |
| Net income 1 | -16.24 | -31.17 | -60.39 | -74.76 | -96.23 | -105.7 |
| Net margin | - | - | - | - | -9,535.14% | -510.25% |
| EPS 2 | -3.780 | -7.560 | -2.740 | -2.414 | -2.493 | -2.531 |
| Free Cash Flow 1 | - | -32.28 | - | -64.5 | -84.52 | -109.1 |
| FCF margin | - | - | - | - | -8,374.77% | -526.7% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 22-08-12 | 23-03-28 | 24-03-28 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -9.575 | -9.945 | -14.39 | -15.52 | -16.14 | -21.05 | -17.67 | -19.09 | -20 | -20.96 | -23.5 | -24 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -9.198 | -8.929 | -12.76 | -13.91 | -14.47 | -19.25 | -16.49 | -18.85 | -19.57 | -20.63 | -23.5 | -24 |
| Net income 1 | -9.198 | -8.929 | -12.76 | -13.91 | -14.47 | -19.25 | -16.49 | -18.85 | -19.57 | -20.63 | -23.5 | -24 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -5.170 | -0.8000 | -0.5800 | -0.6300 | -0.6600 | -0.8700 | -0.7300 | -0.5778 | -0.5567 | -0.5778 | -0.6400 | -0.6650 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-12-15 | 23-03-28 | 23-05-09 | 23-08-11 | 23-11-09 | 24-03-28 | 24-05-14 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 128 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -32.3 | - | -64.5 | -84.5 | -109 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 2.17 | - | 1.69 | 1.65 | 3.56 |
| Capex / Sales | - | - | - | - | 163.53% | 17.2% |
| Announcement Date | 22-08-12 | 23-03-28 | 24-03-28 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.25
USD
Average target price
22.38
USD
Spread / Average Target
+208.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +47.36% | 224M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- ACRV Stock
- Financials Acrivon Therapeutics, Inc.
